Back to News
May 4, 2026 4:00 PM

AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience Corporation (NASDAQ:TWST) shares are down on Monday as the company reported its fiscal 2026 second-quarter financial results.

The life science company reported an adjusted loss of 59 cents, missing the consensus loss of 48 cents.

The sales came in at $110.72 million, beating the consensus of $107.66 million, and the management guidance of $107 million-$108 million.

Management Maintains Profitability Timeline

“We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio. We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while holding gross margin above 52% for the fiscal year,” Emily Leproust, CEO and co-founder of ...